Showing results (81-90 of 693) with videos related to

Sort By:
Pageof 70
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|May 12, 2010
Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosisChih-Huan Chung, Chi-Jung Wu, Hsin-Chun Lee, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|December 12, 2018
Bloodstream infections in hospitalized adults with dengue fever: Clinical characteristics and recommended empirical therapyLing-Shan Syue, Hung-Jen Tang, Yuan-Pin Hung, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 14, 2022
Geographic patterns of Acinetobacter baumannii and carbapenem resistance in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2019Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
Frontiers in Medicine|June 17, 2022
Effects of Inappropriate Administration of Empirical Antibiotics on Mortality in Adults With Bacteraemia: Systematic Review and Meta-AnalysisYuan-Pin Hung, Ching-Chi Lee, Wen-Chien Ko
Expert Opinion on Pharmacotherapy|March 14, 2013
Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infectionsYen-Hsu Chen, Wen-Chien Ko, Po-Ren Hsueh
International Journal of Antimicrobial Agents|October 14, 2022
Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
International Journal of Antimicrobial Agents|May 27, 2023
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
Frontiers in Pharmacology|October 23, 2019
Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant OrganismsNan-Yao Lee, Wen-Chien Ko, Po-Ren Hsueh
Antimicrobial Agents and Chemotherapy|November 22, 2021
Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015-2019Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
International Journal of Antimicrobial Agents|May 19, 2020
Susceptibility of clinical isolates of meticillin-resistant Staphylococcus aureus and phenotypic non-extended-spectrum β-lactamase-producing Klebsiella pneumoniae to ceftaroline in Taiwan: Results from Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018 and Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2018-2019Shio-Shin Jean, Wen-Chien Ko, Po-Ren Hsueh, et al.
Pageof 70